Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Indivior Solutions ordered to pay $289 million in Suboxone case

By Brian Buntz | November 14, 2020

IndiviorA federal judge in Virginia has sentenced opioid-addiction drug maker Indivior Solutions (LON:INDV) to pay $289 million in criminal penalties linked to the marketing of the drug Suboxone, the U.S. Department of Justice announced. 

In all, Indivior will pay a total of $600 million to resolve civil and criminal liabilities for downplaying safety risks tied to Suboxone. 

Randy Ramseyer of the U.S. Attorney’s Office for the Western District of Virginia prosecuted the case against Indivior. 

The company’s former parent, Reckitt Benckiser Group, agreed last year to pay $1.4 billion to the Department of Justice to settle Suboxone-related complaints. The amount was the largest sum the U.S. has recovered in an opioid drug case. 

The opioid-addiction treatment combines the opioid buprenorphine and naloxone, a drug that blocks the effects of opioids. The drug is intended to reduce withdrawal symptoms in opioid addicts. 

Indivior Solutions pleaded guilty thus summer to a single felony related to making false healthcare statements. 

The company also admitted to making false claims regarding the risk of Suboxone sublingual film use in children. 

The company also will disband its Suboxone sales force and avoid promoting the drug to healthcare providers likely to prescribe the medication inappropriately. 

“Combating the opioid epidemic is a top priority for the Department of Justice,” said Acting Assistant Attorney General Jeffrey Bossert Clark of the Justice Department’s Civil Division in prepared remarks. “We will hold drug manufacturers accountable when they make misrepresentations that could affect consumers’ access to opioid addiction treatments.”

Indivior’s former CEO, Shaun Thaxter, pleaded guilty on June 30, 2020, to a misdemeanor related to making false and misleading statements to MassHealth. The court sentenced Thaxter to a six-month prison term and $600,000 in criminal fines and forfeiture. 

Thaxter had been CEO since 2009. 

The company’s former medical director, Tim Baxter, pleaded guilty to a similar charge and is scheduled for sentencing in December. 

 

Tell Us What You Think! Cancel reply

Related Articles Read More >

coronavirus COVID-19 Pfizer
7 core strategies in Biden’s battle against COVID-19
Pfizer-BioNTech vaccine
Cybercriminals manipulated COVID-19 vaccine files before sharing them
Moderna and NIH assessing whether COVID-19 vaccine doses can be halved
Timing of COVID-19 vaccine doses sparks debate  

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards